SRR1071289
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.481
- INFLAMMATORY_RESPONSE+0.446
- IL6_JAK_STAT3_SIGNALING+0.426
- COAGULATION+0.423
- PANCREAS_BETA_CELLS+0.393
- KRAS_SIGNALING_DN+0.373
- ALLOGRAFT_REJECTION+0.349
- ANGIOGENESIS+0.349
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.345
- INTERFERON_ALPHA_RESPONSE+0.315
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.520
- DNA_REPAIR-0.462
- MYC_TARGETS_V2-0.444
- PROTEIN_SECRETION-0.433
- MYC_TARGETS_V1-0.373
- UNFOLDED_PROTEIN_RESPONSE-0.353
- ADIPOGENESIS-0.315
- MITOTIC_SPINDLE-0.287
- PI3K_AKT_MTOR_SIGNALING-0.251
- E2F_TARGETS-0.249
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR818469 | GTEX | — | 0.960 |
| 2 | SRR1389059 | GTEX | — | 0.950 |
| 3 | SRR1467294 | GTEX | — | 0.949 |
| 4 | SRR1329885 | GTEX | — | 0.946 |
| 5 | SRR1317494 | GTEX | — | 0.944 |
| 6 | SRR1408327 | GTEX | — | 0.944 |
| 7 | SRR1352706 | GTEX | — | 0.944 |
| 8 | MDT-AP-1108 | Med | Medulloblastoma | 0.944 |
| 9 | SRR1323536 | GTEX | — | 0.937 |
| 10 | SRR1444932 | GTEX | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.481 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.446 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.426 | Inavolisib | — uncovered |
| COAGULATION | 0.423 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.393 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.373 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.349 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.349 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.345 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.315 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.312 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.304 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.298 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.281 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.261 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.261 | Idelalisib | — uncovered |
| MYOGENESIS | 0.219 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.204 | Inavolisib | — uncovered |
| HYPOXIA | 0.178 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.178 | Inavolisib | — uncovered |